Molecular Inflammation Board at the Center for Personalized Medicine

Recruiting

• Conditions: Psoriasis (PsO); Psoriasis Arthritis; Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis); Spondylarthropathies

• Registration Number: NCT07132333
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

Molecular Inflammation Board at the Center for Personalized Medicine

Detailed Description

Molecular Inflammation Board at the Center for Personalized Medicine

The study objectives are:

To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care

Study Timeline

• Study Start: 2022-11-16
• Status Verified: 2025-08
• Study First Submitted: 2025-08-11
• Study First Submitted QC: 2025-08-19
• Last Update Submitted: 2025-08-19
• Study First Posted: 2025-08-20
• Last Update Posted: 2025-08-20
• Primary Completion: 2032-11
• Study Completion: 2032-11-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
• Given informed consent
• 18 years of age

Exclusion Criteria

• No capacity to consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Therapy persistence	Through study completion, an average of 1 year	Duration of intervention with biological agent

Trial Locations

Locations (1)

University Hospital of Tübingen - Center for Personalized Medicine; 🇩🇪 Tübingen, Germany